CDK4/6 inhibitor resistance in estrogen receptor positive breast cancer, a 2023 perspective von Zhou, Fiona H, Downton, Teesha, Freelander, Allegra, Hurwitz, Joshua, Caldon, C Elizabeth, Lim, Elgene

Volltext

Type 1 Nuclear Receptor Activity in Breast Cancer: Translating Preclinical Insights to the Clinic von Kumar, Sanjeev, Freelander, Allegra, Lim, Elgene

Volltext

Targeting clinical mechanisms of therapy resistance in ER+ breast cancer using an AR agonistic approach von Freelander, Allegra

Volltext bestellen

Molecular Biomarkers for Contemporary Therapies in Hormone Receptor-Positive Breast Cancer von Freelander, Allegra, Brown, Lauren J., Parker, Andrew, Segara, Davendra, Portman, Neil, Lau, Brandon, Lim, Elgene

Volltext

Abstract PD2-02: Combination CDK4/6 inhibition and AR agonism suppresses the growth of CDK4/6 inhibitor resistant breast cancers von Freelander, Allegra, Laven-Law, Geraldine, Eshraghi, Leila, Chia, Kee Ming, Pickering, Marie, Yong, Aliza, Wilkinson, Ashleigh, Alexandrou, Sarah, Caldon, C. Elizabeth, Hickey, Theresa E, Tilley, Wayne D, Lim, Elgene

Volltext

Abstract P4-08-16: Selective Androgen Receptor Modulators in combination with CDK4/6 inhibitors demonstrate anti-cancer activity in preclinical treatment resistant ER+AR+ breast ca... von Freelander, Allegra, laven-Law, Geraldine, Eshraghi, Leila, Geetha, Nimmy, Somerville, Peta, Pickering, Marie, Alexandrou, Sarah, Caldon, C. Elizabeth, Tilley, Wayne D., Hickey, Theresa E., Lim, Elgene

Volltext

Estrogen receptor positive breast cancer patient–derived xenograft models in translational research von Chia, KeeMing, Freelander, Allegra, Kumar, Sanjeev, Parker, Andrew, Segara, Davendra, Portman, Neil, Lim, Elgene

Volltext